IgA Vasculitis in Adults: a Rare yet Challenging Disease.
Henoch-Schönlein purpura
IgA vasculitis (IgAV)
Treatment
Journal
Current rheumatology reports
ISSN: 1534-6307
Titre abrégé: Curr Rheumatol Rep
Pays: United States
ID NLM: 100888970
Informations de publication
Date de publication:
01 07 2021
01 07 2021
Historique:
accepted:
21
04
2021
entrez:
1
7
2021
pubmed:
2
7
2021
medline:
26
11
2021
Statut:
epublish
Résumé
IgA vasculitis (IgAV) is a rare and poorly understood systemic vasculitis in adults. Its diagnosis and treatment remain a challenge. Herein, we review the clinical manifestations, diagnosis, management, and prognosis of IgAV in adults. The clinical course of IgAV in adults appears to be different from pediatric IgAV, especially due to its higher risk of evolving into end-stage renal disease. Rising awareness and interest in adult-onset IgA vasculitis has resulted in recent increasing number of publications on different treatment experiences. However, there is still controversy over the role of glucocorticoid (GC) and different immunosuppressive therapies such as cyclophosphamide, rituximab, and mychophenolate mofetil for more severe IgAV. Data regarding potential benefits of targeting the mucosal immune system, toll-like receptors, complements, and tyrosine kinase inhibitors in the treatment of IgA nephropathy are emerging. High quality evidence or guidelines in the treatment of severe IgAV are lacking and there is still a great need for controlled trials.
Identifiants
pubmed: 34196893
doi: 10.1007/s11926-021-01013-x
pii: 10.1007/s11926-021-01013-x
doi:
Substances chimiques
Immunoglobulin A
0
Rituximab
4F4X42SYQ6
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
50Références
Gardner-Medwin JM, Dolezalova P, Cummins C, Southwood TR. Incidence of Henoch-Schonlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet. 2002;360(9341):1197–202. https://doi.org/10.1016/S0140-6736(02)11279-7 .
doi: 10.1016/S0140-6736(02)11279-7
pubmed: 12401245
Watts RA, Lane S, Scott DGI. What is known about the epidemiology of the vasculitides? Best Pract Res Clin Rheumatol. 2005;19(2):191–207. https://doi.org/10.1016/j.berh.2004.11.006 .
doi: 10.1016/j.berh.2004.11.006
pubmed: 15857791
García-Porrúa C, Calviño MC, Llorca J, Couselo JM, González-Gay MA. Henoch-Schönlein purpura in children and adults: clinical differences in a defined population. Semin Arthritis Rheum. 2002;32(3):149–56. https://doi.org/10.1053/sarh.2002.33980 .
doi: 10.1053/sarh.2002.33980
pubmed: 12528079
Schonlein J. Allgemeine und specielle pathologie und therapie : Nach Seinen Vorlesungen Niedergeschrieben von Einigen Seiner Zuhörer Und Nicht Autorisiert Herausgegeben. 5th ed: Etlinger; 1832.
Henoch E. Uber eine eigentumliche form von purpura. Klin Wochenschr. 1874;11:641.
Heineke MH, Ballering AV, Jamin A, Ben Mkaddem S, Monteiro RC, Van Egmond M. New insights in the pathogenesis of immunoglobulin A vasculitis (Henoch-Schönlein purpura). Autoimmun Rev. 2017;16(12):1246–53. https://doi.org/10.1016/j.autrev.2017.10.009 .
doi: 10.1016/j.autrev.2017.10.009
pubmed: 29037908
Pillebout E. Henoch-Schonlein purpura in adults: outcome and prognostic factors. J Am Soc Nephrol. 2002;13(5):1271–8. https://doi.org/10.1097/01.ASN.0000013883.99976.22 .
doi: 10.1097/01.ASN.0000013883.99976.22
pubmed: 11961015
Mills JA, Michel BA, Bloch DA, Calabrese LH, Hunder GG, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of henoch-schönlein purpura. Arthritis Rheum. 2010;33(8):1114–21. https://doi.org/10.1002/art.1780330809 .
doi: 10.1002/art.1780330809
Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides. Arthritis Rheum. 1994;37(2):187–92. https://doi.org/10.1002/art.1780370206 .
doi: 10.1002/art.1780370206
pubmed: 8129773
Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1–11. https://doi.org/10.1002/art.37715 .
doi: 10.1002/art.37715
Ortiz-Sanjuán F, Blanco R, Hernández JL, et al. Applicability of the 2006 European League Against Rheumatism (EULAR) criteria for the classification of Henoch-Schönlein purpura. An analysis based on 766 patients with cutaneous vasculitis. Clin Exp Rheumatol. 2015;33(2 Suppl 89):S-44–7.
Hočevar A, Rotar Z, Jurčić V, Pižem J, Čučnik S, Vizjak A, et al. IgA vasculitis in adults: the performance of the EULAR/PRINTO/PRES classification criteria in adults. Arthritis Res Ther. 2016;18(1):58. https://doi.org/10.1186/s13075-016-0959-4 .
doi: 10.1186/s13075-016-0959-4
pubmed: 26935833
pmcid: 4774143
Zurada JM, Ward KM, Grossman ME. Henoch-Schönlein purpura associated with malignancy in adults. J Am Acad Dermatol. 2006;55(5):S65–70. https://doi.org/10.1016/j.jaad.2005.10.011 .
doi: 10.1016/j.jaad.2005.10.011
pubmed: 17052537
Audemard-Verger A, Pillebout E, Guillevin L, Thervet E, Terrier B. IgA vasculitis (Henoch–Shönlein purpura) in adults: diagnostic and therapeutic aspects. Autoimmun Rev. 2015;14(7):579–85. https://doi.org/10.1016/j.autrev.2015.02.003 .
doi: 10.1016/j.autrev.2015.02.003
pubmed: 25688001
Kang Y, Park J, Ha Y-J, Kang MI, Park HJ, Lee SW, et al. Differences in clinical manifestations and outcomes between adult and child patients with Henoch-Schönlein purpura. J Korean Med Sci. 2014;29(2):198–203. https://doi.org/10.3346/jkms.2014.29.2.198 .
doi: 10.3346/jkms.2014.29.2.198
pubmed: 24550645
pmcid: 3923997
Blanco R, Martínez-Taboada VM, Rodríguez-Valverde V, García-Fuentes M, Gonzalez-Gay MA. Henoch-Schönlein purpura in adulthood and childhood. Two different expressions of the same syndrome. Arthritis Rheum. 1997;40(5):859–64. https://doi.org/10.1002/art.1780400513 .
doi: 10.1002/art.1780400513
pubmed: 9153547
Hitomi K, Izaki S, Teraki Y, Aso Y, Yokoyama M, Takamura S, et al. Characterization of adult-type IgA vasculitis (Henoch-Schönlein Purpura): a retrospective study of 122 cases. Open Dermatol J. 2014;8(1):51–9. https://doi.org/10.2174/1874372201408010051 .
doi: 10.2174/1874372201408010051
Abbara S, Grateau G, Ducharme-Bénard S, Saadoun D, Georgin-Lavialle S. Association of vasculitis and familial Mediterranean fever. Front Immunol. 2019;10:763. https://doi.org/10.3389/fimmu.2019.00763 .
doi: 10.3389/fimmu.2019.00763
pubmed: 31031761
pmcid: 6473328
Villatoro-Villar M, Crowson C, Makol A, Ytterberg S, Warrington K, Koster M. 170. IGA vasculitis associated with inflammatory bowel disease. A retrospective study. Rheumatology. 2019;58(Supplement_2). https://doi.org/10.1093/rheumatology/kez059.047 .
Gong EJ, Kim DH, Chun JH, Ahn JY, Choi KS, Jung KW, et al. Endoscopic findings of upper gastrointestinal involvement in primary vasculitis. Gut Liver. 2016;10(4):542–8. https://doi.org/10.5009/gnl15198 .
doi: 10.5009/gnl15198
pubmed: 27226428
pmcid: 4933413
Roberts PF, Waller TA, Brinker TM, Riffe IZ, Sayre JW, Bratton RL. Henoch-Schönlein purpura: a review article. South Med J. 2007;100(8):821–4. https://doi.org/10.1097/SMJ.0b013e3180f62d0f .
doi: 10.1097/SMJ.0b013e3180f62d0f
pubmed: 17713309
Pillebout E, Niaudet P. Henoch-Schönlein purpura. Rev Prat. 2008;58(5):507–11.
pubmed: 18524107
Chao HC, Kong MS, Lin SJ. Hepatobiliary involvement of Henoch-Schönlein purpura in children. Acta Paediatr Taiwan. 2000;41(2):63–8.
pubmed: 10927941
Shrestha S. Henoch Schonlein purpura with nephritis in adults: adverse prognostic indicators in a UK population. QJM. 2006;99(4):253–65. https://doi.org/10.1093/qjmed/hcl034 .
doi: 10.1093/qjmed/hcl034
pubmed: 16565522
Kanaan N, Mourad G, Thervet E, Peeters P, Hourmant M, Vanrenterghem Y, et al. Recurrence and graft loss after kidney transplantation for Henoch–Schönlein purpura nephritis: a multicenter analysis. Clin J Am Soc Nephrol. 2011;6(7):1768–72. https://doi.org/10.2215/CJN.00520111 .
doi: 10.2215/CJN.00520111
pubmed: 21734091
Han SS, Sun H-K, Lee JP, Ha JW, Kim SJ, Kim YS. Outcome of renal allograft in patients with Henoch-Schönlein nephritis: single-center experience and systematic review. Transplantation. 2010;89(6):721–6. https://doi.org/10.1097/TP.0b013e3181c9cc4a .
doi: 10.1097/TP.0b013e3181c9cc4a
pubmed: 20010329
Nadrous HF, Yu AC, Specks U, Ryu JH. Pulmonary…Henoch-Schönlein purpura. Mayo Clin Proc. 2004;79(9):1151–7. https://doi.org/10.4065/79.9.1151 .
doi: 10.4065/79.9.1151
pubmed: 15357037
Polizzotto MN, Gibbs SDJ, Beswick W, Seymour JF. Cardiac involvement in Henoch-Schonlein purpura. Intern Med J. 2006;36(5):328–31. https://doi.org/10.1111/j.1445-5994.2006.01061.x .
doi: 10.1111/j.1445-5994.2006.01061.x
pubmed: 16650200
Modi S, Mohan M, Jennings A. Acute scrotal swelling in Henoch-Schonlein purpura: case report and review of the literature. Urol Case Rep. 2016;6:9–11. https://doi.org/10.1016/j.eucr.2016.01.004 .
doi: 10.1016/j.eucr.2016.01.004
pubmed: 27169017
pmcid: 4855902
Garzoni L, Vanoni F, Rizzi M, Simonetti GD, Simonetti BG, Ramelli GP, et al. Nervous system dysfunction in Henoch-Schonlein syndrome: systematic review of the literature. Rheumatology. 2009;48(12):1524–9. https://doi.org/10.1093/rheumatology/kep282 .
doi: 10.1093/rheumatology/kep282
pubmed: 19797041
Tayabali S, Andersen K, Yoong W. Diagnosis and management of Henoch-Schönlein purpura in pregnancy: a review of the literature. Arch Gynecol Obstet. 2012;286(4):825–9. https://doi.org/10.1007/s00404-012-2468-2 .
doi: 10.1007/s00404-012-2468-2
pubmed: 22865032
Lin Q, Min Y, Li Y, Zhu Y, Song X, Xu Q, et al. Henoch–Schönlein purpura with hypocomplementemia. Pediatr Nephrol. 2012;27(5):801–6. https://doi.org/10.1007/s00467-011-2070-z .
doi: 10.1007/s00467-011-2070-z
pubmed: 22271365
Calviño MC, Llorca J, García-Porrúa C, Fernández-Iglesias JL, Rodriguez-Ledo P, González-Gay MA. Henoch-Schönlein purpura in children from Northwestern Spain: a 20-year epidemiologic and clinical study. Medicine (Baltimore). 2001;80(5):279–90. https://doi.org/10.1097/00005792-200109000-00001 .
doi: 10.1097/00005792-200109000-00001
Sais G, Vidaller A, Jucglà A, Servitje O, Condom E, Peyrí J. Prognostic factors in leukocytoclastic vasculitis: a clinicopathologic study of 160 patients. Arch Dermatol. 1998;134(3):309–15. https://doi.org/10.1001/archderm.134.3.309 .
doi: 10.1001/archderm.134.3.309
pubmed: 9521029
Linskey KR, Kroshinsky D, Mihm MC, Hoang MP. Immunoglobulin-A–associated small-vessel vasculitis: a 10-year experience at the Massachusetts General Hospital. J Am Acad Dermatol. 2012;66(5):813–22. https://doi.org/10.1016/j.jaad.2011.06.012 .
doi: 10.1016/j.jaad.2011.06.012
pubmed: 21798626
Jelusic M, Sestan M, Cimaz R, Ozen S. Different histological classifications for Henoch-Schönlein purpura nephritis: which one should be used? Pediatr Rheumatol Online J. 2019;17(1):10. https://doi.org/10.1186/s12969-019-0311-z .
doi: 10.1186/s12969-019-0311-z
pubmed: 30819179
pmcid: 6393980
Trimarchi H, Barratt J, Cattran DC, Cook HT, Coppo R, Haas M, et al. Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. Kidney Int. 2017;91(5):1014–21. https://doi.org/10.1016/j.kint.2017.02.003 .
doi: 10.1016/j.kint.2017.02.003
pubmed: 28341274
Yun D, Kim DK, Oh K-H, Joo KW, Moon KC, Kim YS, et al. MEST-C pathological score and long-term outcomes of child and adult patients with Henoch-Schönlein purpura nephritis. BMC Nephrol. 2020;21(1):33. https://doi.org/10.1186/s12882-020-1691-5 .
doi: 10.1186/s12882-020-1691-5
pubmed: 32000703
pmcid: 6993338
Inagaki K, Kaihan AB, Hachiya A, Ozeki T, Ando M, Kato S, et al. Clinical impact of endocapillary proliferation according to the Oxford Classification among adults with Henoch-Schönlein purpura nephritis: a multicenter retrospective cohort study. BMC Nephrol. 2018;19(1):208. https://doi.org/10.1186/s12882-018-1009-z .
doi: 10.1186/s12882-018-1009-z
pubmed: 30119643
pmcid: 6098628
Ho Kim C, Jin Lim B, Sung Bae Y, Eun Kwon Y, Ly Kim Y, Heon Nam K, et al. Using the Oxford Classification of IgA nephropathy to predict long-term outcomes of Henoch–Schönlein purpura nephritis in adults. Mod Pathol. 2014;27(7):972–82. https://doi.org/10.1038/modpathol.2013.222 .
doi: 10.1038/modpathol.2013.222
Roman C, Dima B, Muyshont L, Schurmans T, Gilliaux O. Indications and efficiency of dapsone in IgA vasculitis (Henoch-Schonlein purpura): case series and a review of the literature. Eur J Pediatr. 2019;178(8):1275–81. https://doi.org/10.1007/s00431-019-03409-5 .
doi: 10.1007/s00431-019-03409-5
pubmed: 31230197
Ronkainen J, Koskimies O, Ala-Houhala M, Antikainen M, Merenmies J, Rajantie J, et al. Early prednisone therapy in Henoch-Schönlein purpura: a randomized, double-blind, placebo-controlled trial. J Pediatr. 2006;149(2):241–7. https://doi.org/10.1016/j.jpeds.2006.03.024 .
doi: 10.1016/j.jpeds.2006.03.024
pubmed: 16887443
Rauen T, Eitner F, Fitzner C, Sommerer C, Zeier M, Otte B, et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med. 2015;373(23):2225–36. https://doi.org/10.1056/NEJMoa1415463 .
doi: 10.1056/NEJMoa1415463
pubmed: 26630142
Lv J, Zhang H, Wong MG, Jardine MJ, Hladunewich M, Jha V, et al. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA. 2017;318(5):432–42. https://doi.org/10.1001/jama.2017.9362 .
doi: 10.1001/jama.2017.9362
pubmed: 28763548
pmcid: 5817603
Pillebout E, Alberti C, Guillevin L, Ouslimani A, Thervet E. The CESAR study group. Addition of cyclophosphamide to steroids provides no benefit compared with steroids alone in treating adult patients with severe Henoch Schönlein purpura. Kidney Int. 2010;78(5):495–502. https://doi.org/10.1038/ki.2010.150 .
doi: 10.1038/ki.2010.150
pubmed: 20505654
Audemard-Verger A, Terrier B, Dechartres A, Chanal J, Amoura Z, le Gouellec N, et al. Characteristics and management of IgA vasculitis (Henoch-Schönlein) in adults: data from 260 patients included in a French multicenter retrospective survey: IgA vasculitis in adults. Arthritis Rheumatol. 2017;69(9):1862–70. https://doi.org/10.1002/art.40178 .
doi: 10.1002/art.40178
pubmed: 28605168
Maritati F, Fenoglio R, Pillebout E, Emmi G, Urban ML, Rocco R, et al. Brief report: rituximab for the treatment of adult-onset IgA vasculitis (Henoch-Schönlein). Arthritis Rheumatol. 2018;70(1):109–14. https://doi.org/10.1002/art.40339 .
doi: 10.1002/art.40339
pubmed: 28973844
Lafayette RA, Canetta PA, Rovin BH, Appel GB, Novak J, Nath KA, et al. A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction. J Am Soc Nephrol. 2017;28(4):1306–13. https://doi.org/10.1681/ASN.2016060640 .
doi: 10.1681/ASN.2016060640
pubmed: 27821627
pmcid: 27821627
Hernández-Rodríguez J, Carbonell C, Mirón-Canelo J-A, Diez-Ruiz S, Marcos M, Chamorro AJ. Rituximab treatment for IgA vasculitis: a systematic review. Autoimmun Rev. 2020;19(4):102490. https://doi.org/10.1016/j.autrev.2020.102490 .
doi: 10.1016/j.autrev.2020.102490
pubmed: 32062030
Ren P, Han F, Chen L, Xu Y, Wang Y, Chen J. The combination of mycophenolate mofetil with corticosteroids induces remission of Henoch-Schönlein purpura nephritis. Am J Nephrol. 2012;36(3):271–7. https://doi.org/10.1159/000341914 .
doi: 10.1159/000341914
pubmed: 22965140
Han F, Chen L, Ren P, le JY, Choong PJ, Wang HJ, et al. Mycophenolate mofetil plus prednisone for inducing remission of Henoch-Schönlein purpura nephritis: a retrospective study. J Zhejiang Univ Sci B. 2015;16(9):772–9. https://doi.org/10.1631/jzus.B1400335 .
doi: 10.1631/jzus.B1400335
pubmed: 26365119
pmcid: 4569685
Shin JI, Park JM, Shin YH, Kim JH, Lee JS, Kim PK, et al. Can azathioprine and steroids alter the progression of severe Henoch-Schönlein nephritis in children? Pediatr Nephrol. 2005;20(8):1087–92. https://doi.org/10.1007/s00467-005-1869-x .
doi: 10.1007/s00467-005-1869-x
pubmed: 15889281
Kalliakmani P, Benou E, Goumenos DS. Cyclosporin A in adult patients with Henoch-Schönlein purpura nephritis and nephrotic syndrome; 5 case reports. Clin Nephrol. 2011;75(04):380–3. https://doi.org/10.5414/CN106553 .
doi: 10.5414/CN106553
pubmed: 21426894
Zhang D-F, Hao G-X, Li C-Z, Yang YJ, Liu FJ, Liu L, et al. Off-label use of tacrolimus in children with Henoch-Schönlein purpura nephritis: a pilot study. Arch Dis Child. 2018;103(8):772–5. https://doi.org/10.1136/archdischild-2017-313788 .
doi: 10.1136/archdischild-2017-313788
pubmed: 29535109
Floege J, Barbour SJ, Cattran DC, Hogan JJ, Nachman PH, Tang SCW, et al. Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2019;95(2):268–80. https://doi.org/10.1016/j.kint.2018.10.018 .
doi: 10.1016/j.kint.2018.10.018
pubmed: 30665568
Liu L-J, Yang Y, Shi S-F, Bao YF, Yang C, Zhu SN, et al. Effects of hydroxychloroquine on proteinuria in IgA nephropathy: a randomized controlled trial. Am J Kidney Dis. 2019;74(1):15–22. https://doi.org/10.1053/j.ajkd.2019.01.026 .
doi: 10.1053/j.ajkd.2019.01.026
pubmed: 30922594
Kiryluk K, Novak J, Gharavi AG. Pathogenesis of immunoglobulin A nephropathy: recent insight from genetic studies. Annu Rev Med. 2013;64(1):339–56. https://doi.org/10.1146/annurev-med-041811-142014 .
doi: 10.1146/annurev-med-041811-142014
pubmed: 23072577
Ring T, Pedersen BB, Salkus G, Goodship THJ. Use of eculizumab in crescentic IgA nephropathy: proof of principle and conundrum? Clin Kidney J. 2015;8(5):489–91. https://doi.org/10.1093/ckj/sfv076 .
doi: 10.1093/ckj/sfv076
pubmed: 26413271
pmcid: 4581393
Rosenblad T, Rebetz J, Johansson M, Békássy Z, Sartz L, Karpman D. Eculizumab treatment for rescue of renal function in IgA nephropathy. Pediatr Nephrol. 2014;29(11):2225–8. https://doi.org/10.1007/s00467-014-2863-y .
doi: 10.1007/s00467-014-2863-y
pubmed: 24924752
National Library of Medicine. Safety and efficacy study of fostamatinib to treat immunoglobulin A (IgA) nephropathy.; 2014. https://ClinicalTrials.gov/show/NCT02112838 .
National Library of Medicine. Efficacy of colchicine to prevent skin relapses in adult’s IgA vasculitis. https://ClinicalTrials.gov/show/NCT04008316 .
Byun J-W, Song H-J, Kim L, Shin J-H, Choi G. Predictive factors of relapse in adult with Henoch-Schönlein purpura. Am J Dermatopathol. 2012;34(2):139–44. https://doi.org/10.1097/DAD.0b013e3182157f90 .
doi: 10.1097/DAD.0b013e3182157f90
pubmed: 22441366